Combined Therapy with Probiotic VSL#3 and Omega-3 Fatty Acids Attenuates Colonic Injury and Inflammation in Chronic DNBS-induced Colitis in Mice

Havvanur Yoldas ILKTAC, Gul KIZILTAN, Asli Devrim LANPIR, Mehmet OZANSOY, Mehmet Y. GUNAL, Sine Ozmen TOGAY, Ilknur KESKIN, Ekrem M. OZDEMIR, and Ulkan KILIC

Accepted September 13, 2021 Published online October 06, 2021 Issue online October 13, 2021

Inflammatory bowel disease (IBD) is a progressive chronic inflammatory disease affecting the gastrointestinal tract with a chronic relapsing and remitting disease course. While there are a number of therapeutic strategies available to treat IBD, a definitive treatment still hasn’t been defined, leading to alternative treatment options including nutritional support. Herein, we planned to investigate the combined impact of probiotics and omega-3 (ω-3) fatty acids on inflammatory response and intestinal epithelium in chronic colitis induced by 2,4-Dinitrobenzenesulfonic acid (DNBS). Fifty BALB/c mice were randomly divided into five groups: non-colitis control, colitis with no treatment applied (control colitis), colitis treated with probiotics (VSL#3), colitis treated with ω-3, and colitis treated with both VSL#3 and ω-3. Colitis was induced by intrarectal administration of 2,4-Dinitrobenzenesulfonic acid (DNBS) in all groups but the non-colitis control group. Ten days after the DNBS period, phosphate-buffered saline (for both the non-colitis control and colitis control groups), VSL#3, ω-3, or VSL#3 + ω-3 treatments were administered intragastrically to their respective groups for 10 days. By analyzing the colonic expression of interleukin IL-6, IL-10, and IL-17A, and interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) levels, results revealed that levels of IFN-γ, IL-17, and TNF-α were significantly higher in the control colitis group when compared with the other groups. The control colitis, colitis + VSL#3, and colitis + ω-3 groups exhibited higher scores of microscopic damage compared to the non-colitis control and colitis + VSL#3 + ω-3 groups. The closest histological image to the non-colitis control group was presented in the colitis + VSL#3 + ω-3 group. The findings indicate that the combined effect of probiotics and ω-3 fatty acids might have a protective effect against colon injury and inflammation by creating synergistic effects. However, more research is needed to understand the exact mechanism of this synergistic effect and to examine how this therapeutic approach can be used in inflammatory bowel diseases.

Key words: Cytokines, strains, essential fatty acids, inflammatory bowel diseases, colonic tissue.
Inflammation begins when the body perceives an undesirable challenge in the body and acts as an important part of innate immunity, which helps to regulate host defense (Bennett et al. 2018). The inflammatory process in the body stimulates the activation of various inflammatory signaling pathways, including the NF-κB, AP1, MAPK, CREB, c/EBP, JAK-STAT, and IRF pathways, thereby triggering the production of adhesion molecules, enzymes, and cytokines to fight against inflammation (Liu et al. 2017; Platanitis & Decker 2018). However, when inflammation becomes chronic, it causes serious damage to the GI tract, especially rectal bleeding, persistent diarrhea, bloody stool, fatigue, and weight loss (Baumgart & Sandborn 2007). Inflammatory bowel diseases (IBD), mainly Ulcerative Colitis (UC) and Crohn’s disease, are chronic systematic disorders of the gastrointestinal tract characterized by uncontrollable mucosal immunity and recurrent inflammatory attacks (Baumgart & Sandborn 2007; Diduch 2017). Although the prevalence of IBD has increased worldwide over the past few decades (Altab et al. 2020), its etiology is still not fully understood (Baumgart & Sandborn 2007; Ghouri et al. 2014). Various medications are recommended in IBD patients to prevent disease progression and control inflammatory reactions, including aminosalicylates, corticosteroids, immunosuppressants, and biologic agents (Tripathi & Feuerstein 2019). However, there is no agent that provides a complete cure in clinical practice (Matsuoka et al. 2018). In addition, these drugs have critical side effects such as GI toxicity, pancreatitis, and immunosuppression (Baumgart & Sandborn 2007; Klein & Eliakim 2010; Tripathi & Feuerstein 2019). Therefore, researchers have been trying for years to find a safer alternative therapeutic approach, such as nutritional therapies and nutritional supplements, to overcome these challenges (Ghouri et al. 2014; Singh et al. 2019). Studies on IBD suggest that genetic, immune, and environmental factors may contribute to the occurrence of these chronic inflammatory disorders (Abegunde et al. 2016). In addition, an elevated inflammatory state can cause damage to the GI tract, causing intestinal epithelial leakage and disruption of intestinal barrier integrity (Lechuga & Ivanov 2017). Therefore, several probiotic treatments have been developed to provide beneficial microbial support to improve gut health (Ghouri et al. 2014; Penner et al. 2005). Probiotics act directly on the epithelial barrier by increasing the production of mucin, antimicrobial peptides, and β-defensin in goblet cells, thereby reducing epithelial permeability to intraluminal pathogens and toxins (Camilleri 2021). This is why probiotic therapy is commonly applied to provide beneficial microbial support to maintain intestinal epithelial barrier integrity and mucosal homeostasis in IBD patients (Ghouri et al. 2014; Parker et al. 2018; Zuo & Ng 2018). Although probiotics are known to have various beneficial effects on health, their benefits vary depending on the type and stage of the disease to be treated and the strain and dose of the probiotics administered (Marcason 2013). A systematic review of randomized controlled trials (RCTs) determining the effect of probiotics, prebiotics, and symbiotics on IBD noted that a VSL #3 probiotic mixture was administered in five of the nine RCTs conducted on patients with UC (Ghouri et al. 2014). All studies investigating VSL #3 supplementation and UC demonstrated that the probiotic blend had significant beneficial effects, including an improvement in clinical activity and an increase in beneficial dendritic cell cytokines in UC patients. However, these RCTs had some limitations, including a high placebo response rate and short administration period (Ghouri et al. 2014). Therefore, more studies are needed to clarify the precise efficacy of these probiotics on IBD patients. Omega-3 (ω-3) fatty acids are long-chain fatty acids well-known for their strong anti-inflammatory properties due to the anti-inflammatory activity of ω-3 derived eicosanoids (Hussein et al. 2019). Studies on IBD show that ω-3 can play a protective role during the inflammatory process of IBD by providing substrates for the production of protectins, resolvins, and maresins that regulate and attenuate inflammatory conditions in IBD and lead to remission of IBD (Durkin et al. 2021; Marton et al. 2019). However, there are still many unknowns about the efficacy of ω-3 fatty acids on IBD (Barbalho et al. 2016). Therefore, the effect of ω-3 fatty acids on IBD needs further clarification. To our knowledge, no studies have investigated the application of probiotics supplemented with ω-3 fatty acids on the intestinal epithelium and inflammatory response in IBD patients/animal models. Therefore, we aimed to determine the combined effect of probiotics and 3 fatty acids on the inflammatory response and intestinal epithelium in mice with chemically induced chronic colitis.

Material and Methods

The study received ethical approval from the Istanbul Medipol University Experimental Animals Research Committee (12/2014, no. 38328770/83). All procedures involved in animal experiments were performed in accordance with the ‘Guide for the Care and Use of Laboratory Animals’ prepared by the National Institute of Health (National Research Council (US) Committee 2011). The sample size was calculated based on the tissue TNF-α values of colitis-induced mice in a previous experimental study (Soyturk et al. 2012). The power analysis showed that a sample size of 6 mice/group has an 80% power to detect an ES of 1.98 pg/ml or an 8% change, assuming a 5% significance level and a two-sided test. The attrition rate is expected to be around 10-20% in ani-
mal studies involving acute treatments (CHIARAN & KANTHARIA 2013). However, this rate may be higher in long-term studies in which chronic disease is triggered (HOLMAN et al. 2016). Therefore, we included 10 mice per group based on an expectation of 40% attrition from the experimental treatment.

Animals
Fifty male BALB/c mice weighing 20-30 g (6-8 weeks old) were obtained from the Istanbul Medipol University Medical Research Center (MEDITAM). The mice were housed in standard polypropylene cages at 20 ± 1°C with 50% ± 5% humidity on a 12-hour light/dark cycle at the Istanbul Medipol University Regenerative and Restorative Medicine Research Center (REMER) Animal Laboratory, fed with standard chow and water ad libitum, and weighed daily throughout the experiments. After a one-week acclimatization period, the mice were randomly assigned to five groups (n= 10/group): control non-colitis, control colitis, treated with probiotics, treated with ω-3 fatty acids, and treated with both probiotics and ω-3 fatty acids. During the study period, four mice each from the control non-colitis, control colitis, ω-3, and probiotics plus ω-3 groups, and five mice from the probiotic group died due to aspiration or both aspiration and colitis, leading to the continuation of the experiment with fewer mice planned for inclusion for the probiotic group at the beginning of the study.

Induction of colitis using Dinitrobenzene Sulfonic Acid and experimental design
Chronic moderate colitis was induced using a method previously described (MARTIN et al. 2014). The experimental protocol implemented in the study included acute colitis induction with Dinitrobenzene sulfonic acid (DNBS), a recovery period, reactivation of colitis with DNBS, and therapeutic treatment with gavage. Before starting the protocol, a 10 cm long piece of PE tubing (ClayAdams, Parsippany, NJ, USA) attached to a tuberculin syringe was inserted 3.5 cm into the colon after the mice were anesthetized with enflurane (Abbott, Abbott Park, IL, USA). The mice in the colitis groups were treated intercolonially with 200 mg/kg DNBS dissolved in 30 % ethanol via the PE tube for three days, while the non-colitis control group was administered phosphate-buffered saline (PBS) only (Sigma-Aldrich, USA). A 6% sucrose solution was administered to the mice through their drinking water for the first three days to prevent dehydration. A 10-day recovery period (no treatment, fed and allowed to drink water ad libitum) was provided for all groups after the 3-day DNBS administration. The treatment groups were administered probiotics, ω-3, or both together for ten days from day 14 following the recovery period while the non-colitis control and control colitis groups received PBS. During the treatment period, the colitis was reactivated on days 21 to 24 by administering 100 mg/kg DNBS solution through the PE-tube. Mice were killed by cervical dislocation on day 24. The study protocol is detailed in Figure 1.

Disease activity index
Calculation of Disease Activity Index (DAI) is presented in Table 1 (MURPHY et al. 1993). The DAI scores were calculated daily for each mouse throughout the study period.

Probiotic and omega-3 administration
Ten days after colitis induction, the groups received probiotics, ω-3, probiotic plus ω-3, or PBS alone (control non-colitis and control colitis groups) for ten days (day 14-23). The VSL#3 probiotic mixture was

![Fig. 1. Experimental protocol.](image-url)
prepared daily for ten days, dissolved in 200 ml drinking water, and administered intragastrically to the probiotic and probiotic plus ω-3 groups. VSL#3 is a mixture of one billion CFU of freeze-dried probiotics in one capsule, consisting of eight bacterial strains including three strains of bifidobacteria (B. longum, B. infantis, and B. breve), four strains of lactobacilli (L. acidophilus, L. paracasei, L. delbrueckii subsp. bulgaricus, and L. plantarum), and Streptococcus salivarius subsp. thermophilus (Sigma-Tau Pharmaceuticals Gaithersburg, MD, USA).

Additionally, mice in the ω-3 and probiotic plus ω-3 groups received a 300 mg/kg dose of ω-3 fatty acids intragastrically for ten days. The ω-3 administered was the soft gel form of ω-3 containing 504 mg of EPA and 378 mg of DHA per capsule (Omega 950, Solgar, Turkey). The ω-3 dose was determined according to the Health Canada Draft Guidelines, which states that it is the therapeutically effective dose to achieve a human equivalent dose of 3.0 g/day (REAGAN-SHAW et al. 2008).

**Colonic tissue collection**

The entire colon was cleaned after exposing the abdominal cavity with a midline laparotomy. The colon was opened longitudinally and half was immediately placed in a formalin solution for histopathological examination, while the remainder was snap-frozen in liquid nitrogen and stored at -80°C for analysis of inflammatory cytokines.

**Tissue homogenization and determination of inflammatory cytokines in tissue homogenates**

To prepare tissue homogenates, the colon tissue was homogenized in 400 ml of Tris-HCl buffer containing protease inhibitors (Sigma, Aldrich) in a Tissue Lyser at pH 7.4 at 0-4°C. The homogenates were then centrifuged at 14,000 x g for 30 minutes and the supernatants were collected for inflammatory cytokine analysis. Five pro-inflammatory cytokines, including interferon-gamma (IFN-γ), interleukin IL-6, IL-10, and IL-17, and tumor necrosis factor-alpha (TNF-α) in tissue homogenates were quantified using the Mouse ELISA Kit (BioLegend, San Diego, USA) according to the manufacturer’s instructions. Cytokines were analyzed using a Magpix Luminex System (Austin, Texas, USA) according to the manufacturer’s instructions. Briefly, primary antibodies for each cytokine were immobilized on magnetic beads and after overnight incubation at +4°C, samples were incubated with a streptavidin-phycoerythrin solution at room temperature in the dark. The samples were then measured luminometrically. The data obtained were evaluated using X PONENT software.

**Histological evaluation**

The colon was fixed in 10% formaldehyde and then processed for paraffin embedding and cut into 5 μm thick sections. Paraffin blocks were stained with hematoxylin and eosin (H&E; Merck, Darmstadt, Germany) for histological scoring using light microscopy (Axio V 16) by a pathologist blinded to the study. The colon was examined under a light microscope at x16 magnification by the same pathologist. Microscopic colitis was assessed using normal morphological structure, density of goblet cells, presence of crypts, and lymphoid tissue and scored according to epithelial and infiltration status as described (OBERMEIER et al. 1999) (Table 2). A numerical score was calculated for each mouse by summing the epithelium and infiltration scores.

**Statistical analysis**

Statistical analysis was performed using SPSS (version 22.0). A one-way ANOVA was performed to compare the differences between the experimental
groups. Levene’s test was used to determine the homogeneity of variances. A p-value of <0.05 was considered significant. When an overall significance was observed, pairwise posthoc analyses were run using Tukey’s test to test the probability of where the differences actually came from. Results were expressed as mean ± standard error of the mean (SEM) and presented as bar graphs.

**Results**

Changes in body weight and food and water intake before the experimental period

No differences were observed in changes in body weight, or food and water intake over the 1-week acclimatization period (data not shown).

Characterization of DNBS-induced colitis

While the decrease in body weight percentage was higher in the control colitis group than in the other groups, there was no significant difference between the other groups (Figure 2). The total microscopic damage scores were also significantly greater in the control colitis group compared to the other groups (Figure 3). Furthermore, a significant difference was detected in histological changes between the control colitis and non-colitis control groups (Figure 4). The control colitis group had higher goblet cell depletion, morphologic derangements, and loss of crypt structures compared to the non-colitis control group. For daily DAI index scores, a significant increase in DAI index was observed in the DNBS-treated mouse groups compared to the non-colitis control group (p<0.05), indicating the presence and activation of colitis as a result of DNBS administration.

Alterations in disease activity index scores monitored daily

We monitored colitis-related clinical symptoms (weight change %, stool consistency, and presence of blood in the stool) on a daily basis to determine the severity of colitis (Figure 5). After the second day of acute colitis induction, a significant increase in DAI scores was detected in all DNBS-treated groups, with a significant difference compared to the non-colitis control group. The DAI scores of the VSL #3 plus w-3 group were significantly lower than the control colitis groups. A significant reduction in colitis severity was
observed in mice treated with VSL#3 plus ω-3, including little or no blood in the stool and an increase in stool consistency.

Effects of therapeutic treatment on pro-inflammatory cytokines in colonic tissues

Figure 6 presents the concentrations of proinflammatory cytokines in colonic tissue after the experimental period. Tissue concentrations of IFN-γ were found to be significantly higher in the control colitis group (63.6 ± 10.3 pg/mg protein) compared to the non-colitis control group (27.0 ± 7.8 pg/mg protein) (p<0.05). Lower levels of IFN-γ were also observed in the VSL#3 (26.2 ± 3.1 pg/mg protein) and VSL#3 plus-3 (31.4 ± 6.8 pg/mg protein) groups compared to the control colitis group.

As shown in Figure 6, higher IL-6 concentrations and lower IL-10 levels were observed in the control colitis group compared to the other groups; however, the differences were not statistically significant.

IL-17A expression was significantly increased in the control colitis group (257.8 ± 34.7 pg/mg protein) compared to the other groups (p<0.05) (Figure 3).
However, no meaningful difference was detected between the treatment groups.

Lower TNF-α concentrations were observed in the VSL#3 (36.4 ± 7.7 pg/mg protein), ω-3 (67.0 ± 13.5 pg/mg protein), and VSL#3 plus ω-3 (52.6 ± 13.5 pg/mg protein) groups compared to the control colitis group (128.0 ± 15.2 pg/mg protein) (p<0.05) (Figure 6).

Microscopic damage scores

The microscopic damage score of the experimental groups is presented in Figure 3. The highest microscopic colitis score (7.8 ± 0.1) was found in the control colitis group compared to the other groups (p<0.0001). Comparing the therapeutic treatment groups, the VSL#3 plus ω-3 group showed a lower damage score than that observed in the VSL#3 and ω-3 groups. In addition, the score observed in the VSL#3 + ω-3 group (0.6 ± 0.2) was similar to the non-colitis control group (p>0.05).

Histopathological results

The histopathological appearance of representative H&E stained sections of colonic tissue is shown in Figure 4. No histopathological abnormalities and disordered morphology were detected in the non-colitis control group. In contrast, the control colitis group showed significant differences compared to the non-colitis control group, such as an alteration of crypt pathology, a significant reduction in goblet cells, and a diffusion of lymphoid tissue extending from the submucosa to the lumen. In the VSL#3-treated group, normal morphology was generally preserved; however, a disappearance in crypt structure in a limited area and a reduction in goblet cells was observed. The histological images of the ω-3 group were quite similar to the VSL#3 group, except that crypt structures disappeared in a more limited area. The morphology of the VSL#3 + ω-3 group including the regular, single-layer prismatic epithelium rich in crypt and goblet cells was quite similar to that of the non-colitis control group. In addition, lymphoid tissue was observed in a limited area in the VSL#3 + ω-3 group.

Discussion

The current study evaluated the effect of VSL#3 or ω-3 alone or the combination of the two supplements on chronic DNBS-induced colitis in mice. Our main findings confirmed our hypothesis by showing that the administration of probiotics in combination with ω-3 is more effective in managing chronic DNBS-induced colitis by preserving intestinal mucosal morphology, and alleviating microscopic damage and disease activity. Administration of VSL#3 alone and in combination with ω-3 reduced the concentrations of IFN-γ and TNF-α, the well-known proinflammatory cytokines that are elevated by colitis induction.
Fig. 6. Tissue inflammatory cytokine levels of the experimental groups. A: Tissue interleukin-6 levels; B: Tissue interleukin-10 levels. C: Tissue interleukin-17 levels. D: Tissue tumor necrosis factor alpha (TNF-α) levels. E: Tissue interferon-gamma (IFN-γ) levels. The results are presented as the mean ± SEM. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Control non-colitis group (n=6); Control colitis group (n=6); VSL#3 group (n=5); omega-3 (w-3) group (n=6); VSL#3+omega group (n=6).
Before evaluating the efficacy of the therapeutic treatment applied in this study, we checked whether colitis occurred with DNBS induction. DNBS-induced colitis is a well-defined experimental model of UC that exhibits various morphological and pathophysiological features similar to human UC (MORAMPUDI et al. 2014). The specific mechanism of colitis induction is still not well defined (RANDHAWA et al. 2014). However, it has been reported that DNBS administration changes the histopathological morphology of colon tissue, disrupts the intestinal mucosal barrier, triggers proinflammatory response, and worsens gastrointestinal symptoms such as diarrhea and bloody stool (MARTIN et al. 2014; MORAMPUDI et al. 2014; RANDHAWA et al. 2014). Our findings demonstrate that the DNBS-treated groups exhibited disordered colonic morphology, including a loss of goblet cells and crypt structures compared to the non-colitis control group. In addition, greater weight loss was observed in the DNBS-induced colitis groups. This may be attributed to the severe diarrhea that progressively increased from the second day of DNBS administration and sharp decrease in food intake (data not shown). Furthermore, higher DAI and microscopic colitis scores were observed in the control colitis group. Considering all these data, it is well-confirmed that colitis was induced by DNBS in the mice.

Studies have revealed that treatment with probiotics (CHEN et al. 2019; DUARY et al. 2012; ISIDRO et al. 2017; ŠTOFILOVÁ et al. 2017) or ω-3 (CAMUESCO et al. 2005; REIFEN et al. 2015; TYAGI et al. 2012) affects the pro/anti-inflammatory cytokine balance by reducing the production of proinflammatory cytokines and by reducing mucosal inflammation during IBD. Although treatment with ω-3 appears to be beneficial for reducing inflammation in patients with IBD (CAMUESCO et al. 2005; REIFEN et al. 2015), several studies have demonstrated that it fails to achieve its beneficial effects during IBD relapse (HAWTHORNE et al. 1992; TURNER et al. 2007). Therefore, we aimed to determine whether treatment with ω-3 in combination with VSL #3 could provide its beneficial effects on reducing inflammation and upregulating cytokine balance, particularly during the relapse of IBD. A number of proinflammatory cytokines, including TNF-α, IL-6, IL-17A, and IFN-γ, are well-known for their roles in inducing inflammation-related gene expressions, thus triggering the inflammatory cascade and damaging colon tissue during the pathological progression of UC (BAUMGART & SANDBORN 2007; MUZES et al. 2012). Studies on UC patients have revealed that the colonic tissue concentrations of TNF-α and IL-6 are higher during the active phase compared to that in patients in remission (ATREYA & N EURATH 2005; BENTO et al. 2012). In this study, we observed that TNF-α concentrations were lower in all therapeutic groups than in the control colitis and non-colitis control groups. However, no meaningful difference was detected in IL-6 levels among all experimental groups. The exact reason why tissue IL-6 expressions did not differ between groups is unclear. One explanation could be that it is related to the chronic experimental model applied in the study. IL-6 is a multifunctional cytokine that is of great importance on both pro- and anti-inflammatory responses (ATREYA & N EURATH 2005). While it is well-known that IL-6 expression by monocytes and macrophages increases sharply in response to any inflammatory condition to initiate mucosal immunity, its overexpression is often associated with uncontrolled inflammatory processes (ATREYA & N EURATH 2005; MUZES et al. 2012; TANAKA et al. 2014). In the present study, reactivation of DNBS-induced colitis may have caused a dysregulation of the IL-6 expression levels in the studied mice colon tissue.

In addition, IL-17A and IFN-γ are other proinflammatory cytokines characterized by their involvement in the pathogenesis of IBD (GÁLVEZ 2014; MUZES et al. 2012). It is known that T helper (Th) cells are responsible for the stimulation and release of these proinflammatory cytokines during IBD processes (GÁLVEZ 2014). We found that IL-17A and IFN-γ expression rates were higher in the control colitis group than in the control group without colitis. While IL-17A concentration did not differ between therapeutic support groups, IFN-γ levels were found to be lower in groups supplemented with VSL #3 alone and in combination with ω-3. One explanation for the similar results of IL-17A levels between treatment groups is that all therapeutic approaches may have similar favorable effects on the treatment of DNBS-induced colitis. However, the concentration of IL-10, an anti-inflammatory cytokine known for its therapeutic role in controlling inflammatory processes during IBD, was similar in all groups, inconsistent with other animal studies supplementing VSL #3. With all the results in mind, treatment with VSL #3, a probiotic supplement well characterized for its beneficial effect on regulating gut barrier function, anti-inflammatory cytokine expression, and gut microbial composition (CHENG et al. 2020; ISIDRO et al. 2017; SÖOD et al. 2009), supplemented with ω-3 may provide beneficial results, including a significant decrease in TNF-α and IFN-γ. More work is required to elucidate the cytokine response during induction of chronic colitis.

Our results on histological examination, DAI, and microscopic scores shed light on determining mucosal barrier function and histopathological changes during chronic DNBS-induced colitis in mice. Mucosal damage characterized by infiltration of proinflammatory cells is one of the most common characteristics of UC. We found that co-administration of VSL #3 and ω-3 resulted in better morphologic outcomes, including the higher presence of crypt and goblet cells, indicating a lesserening of tissue damage. These results are consistent with previous animal
Our findings showed that treatment with VSL #3 in combination with ω-3 significantly reduced mucosal damage, gastrointestinal disturbances, and histopathological change, thus significantly suppressing the severity of chronic DNBS-induced colitis. To our knowledge, this is the first study to include the application of VSL #3 combined with ω-3 in a chronic colitis model. These findings suggest that this combined therapy may contribute as a complementary therapy in chronic colitis. However, further studies involving detailed analyses of cytokine response and microbiome samples are needed before they can be applied to human studies.

Funding
This project was supported by The Scientific and Technological Research Council of Turkey (TUBITAK) (Grand Number: 1155679, 2015).

Author Contributions

Conflict of Interest
All authors read and approved the final version of the manuscript. The authors have no financial or personal conflicts of interest to declare.

References
BENNETT J.M., REEVES G., BILLMAN G.E., STURMBERG J.P. 2018. Inflammation-nature’s way to efficiently respond to all types of challenges: Implications for understanding and manag-

Studies suggesting a preservative role of VSL #3 (CHEN et al. 2019; ISIDRO et al. 2017; SOOD et al. 2009) or ω-3 (CAMUESCO et al. 2005; REIFEN et al. 2015; TYAGI et al. 2012) alone on decreasing macroscopic score and inflammation, and improving histopathology in IBD.

The protection of goblet cells during colitis prevents DNBS-induced colonic mucosal damage and increased inflammation, and increases their secretion, providing an intact mucosal membrane (GRONDIN et al. 2015; TYAGI et al. 2009). Goblet cell depletion and damaged cryptic structures are considered indicators of chronic inflammation during colitis (HENDRICKSON et al. 2002). In this study, all groups except VSL #3 plus ω-3 treatment showed a depletion of goblet cells and loss of cryptic structure, suggesting that co-administration of VSL #3 with ω-3 in mice with chronic colitis reduced the severity of mucosal damage and provided colonic maintenance.

Our findings need to be evaluated in light of potential limitations. Initially, although we started this study with fifty mice, we completed the study with five mice in the probiotic group and six in each of the other groups. It is important to note that the main cause of death was aspiration or both aspiration and colitis, not the treatment administered. Furthermore, the deaths did not affect the power analysis of the study, as we included 10 mice per group based on the expectation of 40% attrition from the experimental treatment in which chronic colitis was induced. Second, we did not analyze the gut microbiome composition. Further studies should include microbiome analysis using high-throughput sequencing technologies to better identify the gut microbiome and potential interactions between microbes and metabolic pathways while investigating the combined effect of ω-3 and probiotic supplementation during chronic colitis. Our study has many strengths. The inclusion of both a non-colitis control and control colitis group provided a better understanding of both the severity of colitis and the potential impact of therapeutic treatments. We administered both supplements at doses indicated as suitable for compliance in human studies. We applied a chronic colitis model involving reactivation of colitis. Since we know that chronic inflammation is common in IBD patients, the application of the chronic colitis model allowed us to obtain more realistic results.

Conclusion
Our findings showed that treatment with VSL #3 in combination with ω-3 significantly reduced mucosal damage, gastrointestinal disturbances, and histopathological change, thus significantly suppressing the severity of chronic DNBS-induced colitis. To our knowledge, this is the first study to include the application of VSL #3 combined with ω-3 in a chronic colitis model. These findings suggest that this combined therapy may contribute as a complementary therapy in chronic colitis. However, further studies involving detailed analyses of cytokine response and microbiome samples are needed before they can be applied to human studies.


